Who Pays My Doctor?

Healthcare provider profile · identity verified

Benjamin James Epstein, DMSC, PA-C

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · DAVIDSON, NC · NPI 1205295409

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Benjamin James Epstein, DMSC, PA-C received $139,948.37 in general payments during 2025 across 605 reported records.

ABBVIE INC. accounted for 26.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 31 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Dyanavel Xr, Ingrezza, Lybalvi, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Auvelity by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ingrezza by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trintellix by this doctor in 2024.

Tris Pharma Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dyanavel XR as an associated drug or biological on 17868 records involving 7985 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Dyanavel Xr by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$139,948.37

605 reported records · 22 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $37,143.5226.5%1102025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $37,020.9426.4%952025
Collegium Pharmaceutical, Inc. Unresolved — no canonical attribution shown $19,231.5213.7%462025
Alkermes, Inc. Unresolved — no canonical attribution shown $14,591.8410.4%602025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $14,466.2810.3%562025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $9,256.636.6%362025
Neos Therapeutics, LP Unresolved — no canonical attribution shown $2,439.691.7%142025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $1,902.901.4%182025
AYTU BioPharma, Inc. Unresolved — no canonical attribution shown $1,300.000.9%22025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $420.160.3%312025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $378.460.3%212025
Supernus Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $350.630.2%222025
Bausch Health US, LLC Unresolved — no canonical attribution shown $334.020.2%182025
Noven Therapeutics, LLC Unresolved — no canonical attribution shown $232.410.2%102025
Novo Nordisk Inc Unresolved — no canonical attribution shown $207.620.1%132025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $164.080.1%52025
Lundbeck LLC Unresolved — no canonical attribution shown $161.310.1%142025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $148.030.1%262025
Corium, LLC Unresolved — no canonical attribution shown $90.710.1%42025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $70.300.1%22025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $21.440.0%12025
Tris Pharma Inc Unresolved — no canonical attribution shown $15.880.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$68,935.0048
Honoraria$29,413.0017
Travel and Lodging$19,691.1276
Consulting Fee$11,585.008
Food and Beverage$10,159.25455
Compensation for serving as faculty or as a speaker for a medical education program$165.001

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $36,935.54 92 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $36,773.36 105 2025
Source payment records
Jornay PM
Normalized: jornay pm		 Drug Collegium Pharmaceutical, Inc. $19,231.52 46 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $14,591.84 60 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14,466.28 56 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $7,976.63 35 2025
Source payment records
Adzenys XR-ODT
Normalized: adzenys xr odt		 Drug Neos Therapeutics, LP $1,389.69 11 2025
Source payment records
Cotempla XR-ODT
Normalized: cotempla xr odt		 Drug AYTU BioPharma, Inc. $1,300.00 2 2025
Source payment records
EXXUA
Normalized: exxua		 Drug Neos Therapeutics, LP $1,050.00 3 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $657.92 27 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $527.96 33 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $420.16 31 2025
Source payment records
Qelbree
Normalized: qelbree		 Drug Supernus Pharmaceuticals, Inc. $350.63 22 2025
Source payment records
APLENZIN
Normalized: aplenzin		 Drug Bausch Health US, LLC $334.02 18 2025
Source payment records
WELLBUTRIN
Normalized: wellbutrin		 Drug Bausch Health US, LLC $334.02 18 2025
Source payment records
Xelstrym
Normalized: xelstrym		 Drug Noven Therapeutics, LLC $232.41 10 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $221.85 15 2025
Source payment records
Wegovy
Normalized: wegovy		 Drug Novo Nordisk Inc $176.43 11 2025
Source payment records
TRINTELLIX
Normalized: trintellix		 Drug Takeda Pharmaceuticals U.S.A., Inc. $148.03 26 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc $113.03 2 2025
Source payment records
QULIPTA
Normalized: qulipta		 Drug ABBVIE INC. $95.16 4 2025
Source payment records
UBRELVY
Normalized: ubrelvy		 Drug ABBVIE INC. $95.16 4 2025
Source payment records
Azstarys
Normalized: azstarys		 Drug Corium, LLC $90.71 4 2025
Source payment records
Sunosi
Normalized: sunosi		 Drug Axsome Therapeutics, Inc. $85.40 3 2025
Source payment records
REJOYN
Normalized: rejoyn		 Device Otsuka Pharmaceutical Development & Commercialization, Inc. $70.30 2 2025
Source payment records
  • 2025-09-18 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $48.92 · Open Payments source
  • 2025-12-03 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $21.38 · Open Payments source
Secuado
Normalized: secuado		 Drug Noven Therapeutics, LLC $55.90 7 2025
Source payment records
INVEGA SUSTENNA
Normalized: invega sustenna		 Drug Janssen Pharmaceuticals, Inc $51.05 3 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $21.44 1 2025
Source payment records
Dyanavel XR
Normalized: dyanavel xr		 Drug Tris Pharma Inc $15.88 1 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $11.81 2 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $11.81 2 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
Auvelity
auvelity		 2025 Auvelity 2024 19
Beneficiary count suppressed		 exact normalized Medicare Part D
Dyanavel XR
dyanavel xr		 2025 Dyanavel Xr 2024 13
Beneficiary count suppressed		 exact normalized Medicare Part D
INGREZZA
ingrezza		 2025 Ingrezza 2024 22
Beneficiary count suppressed		 exact normalized Medicare Part D
LYBALVI
lybalvi		 2025 Lybalvi 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
TRINTELLIX
trintellix		 2025 Trintellix 2024 35
Beneficiary count suppressed		 exact normalized Medicare Part D
VRAYLAR
vraylar		 2025 Vraylar 2024 46
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 VRAYLAR
open payments reported associated product		 CMS Open Payments — General Payments
377741 supporting records · 62704 recipient NPIs · example record 1201352550 		Vraylar · 2024
Exact normalized brand match · 1 Part D row		 46 suppressed by CMS
Alkermes, Inc.
Exact reporting entity; no affiliate inference		 2025 LYBALVI
open payments reported associated product		 CMS Open Payments — General Payments
93784 supporting records · 20135 recipient NPIs · example record 1222428566 		Lybalvi · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Axsome Therapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Auvelity
open payments reported associated product		 CMS Open Payments — General Payments
116023 supporting records · 35298 recipient NPIs · example record 1235293064 		Auvelity · 2024
Exact normalized brand match · 1 Part D row		 19 suppressed by CMS
Neurocrine BioSciences, Inc.
Exact reporting entity; no affiliate inference		 2025 INGREZZA
open payments reported associated product		 CMS Open Payments — General Payments
126456 supporting records · 27390 recipient NPIs · example record 1242766729 		Ingrezza · 2024
Exact normalized brand match · 1 Part D row		 22 suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc.
Exact reporting entity; no affiliate inference		 2025 TRINTELLIX
open payments reported associated product		 CMS Open Payments — General Payments
37075 supporting records · 14402 recipient NPIs · example record 1223616266 		Trintellix · 2024
Exact normalized brand match · 1 Part D row		 35 suppressed by CMS
Tris Pharma Inc
Exact reporting entity; no affiliate inference		 2025 Dyanavel XR
open payments reported associated product		 CMS Open Payments — General Payments
17868 supporting records · 7985 recipient NPIs · example record 1192249449 		Dyanavel Xr · 2024
Exact normalized brand match · 1 Part D row		 13 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
ClonazepamClonazepam12924
LamotrigineLamotrigine10021
Trazodone HclTrazodone Hcl8722
Bupropion XlBupropion Hcl8619
AlprazolamAlprazolam8511
AripiprazoleAripiprazole6812
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine61suppressed
Duloxetine HclDuloxetine Hcl5814
Fluoxetine HclFluoxetine Hcl5514
Buspirone HclBuspirone Hcl5215
DiazepamDiazepam49suppressed
VraylarCariprazine Hcl46suppressed
Escitalopram OxalateEscitalopram Oxalate44suppressed
Propranolol HclPropranolol Hcl4412
Quetiapine FumarateQuetiapine Fumarate39suppressed
Lithium Carbonate ErLithium Carbonate37suppressed
LorazepamLorazepam37suppressed
TrintellixVortioxetine Hydrobromide35suppressed
GabapentinGabapentin34suppressed
Venlafaxine Hcl ErVenlafaxine Hcl30suppressed
Alprazolam ErAlprazolam27suppressed
Sertraline HclSertraline Hcl27suppressed
Vilazodone HclVilazodone Hcl26suppressed
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25suppressed
MirtazapineMirtazapine25suppressed
TemazepamTemazepam25suppressed
Bupropion Hcl SrBupropion Hcl24suppressed
VyvanseLisdexamfetamine Dimesylate23suppressed
IngrezzaValbenazine Tosylate22suppressed
OlanzapineOlanzapine22suppressed
TopiramateTopiramate21suppressed
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20suppressed
Lisdexamfetamine DimesylateLisdexamfetamine Dimesylate20suppressed
AuvelityDextromethorphan Hbr/Bupropion19suppressed
EszopicloneEszopiclone19suppressed
RisperidoneRisperidone19suppressed
Citalopram HbrCitalopram Hydrobromide17suppressed
Zolpidem TartrateZolpidem Tartrate17suppressed
Hydroxyzine HclHydroxyzine Hcl14suppressed
Lurasidone HclLurasidone Hcl14suppressed
Adderall XrDextroamphetamine/Amphetamine13suppressed
Dyanavel XrAmphetamine13suppressed
Zolpidem Tartrate ErZolpidem Tartrate13suppressed
LybalviOlanzapine/Samidorphan Malate12suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $139,948.37 · 605 records ABBVIE INC. ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, Cotempla XR-ODT, Dyanavel XR, EXXUA, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, QULIPTA, Qelbree, REJOYN, REXULTI, SPRAVATO, Secuado, Sunosi, TRINTELLIX, UBRELVY, UZEDY, VRAYLAR, WELLBUTRIN, Wegovy, Xelstrym 6 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error